Targeting c-Kit mutations: Basic science to novel therapies

Leukemia Research

Volumn 28, Issue SUPPL. 1, 2004, Pages 11-20

  Sattler, Martin ^a,b,c   Salgia, Ravi ^d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

c Kit inhibition; Kit; Mutation; Receptor tyrosine kinase; Signal transduction

Indexed keywords

6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; AGL 2043; CISPLATIN; ENZYME INHIBITOR; IMATINIB; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; POLYPHOSPHOINOSITIDE; PROTEIN KINASE C; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; PYRIMIDINE DERIVATIVE; QUINOXALINE DERIVATIVE; RAS PROTEIN; SEMAXANIB; STAT PROTEIN; STEM CELL FACTOR RECEPTOR; SU 6597; SU 9529; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL TRANSFORMATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME MODIFICATION; ENZYME STRUCTURE; ENZYMOLOGY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MASTOCYTOSIS; METASTASIS; MOLECULAR MECHANICS; MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SIGNAL TRANSDUCTION; TESTIS CANCER; TISSUE DISTRIBUTION; TUMOR GROWTH;

EID: 1342321789     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.10.004     Document Type: Article

References (139)

1. Yarden Y., Kuang W.J., Yang-Feng T., Coussens L., Munemitsu S., Dull T.J.et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 6:1987;3341-3351.
2. Yarden Y., Escobedo J.A., Kuang W.J., Yang-Feng T.L., Daniel T.O., Tremble P.M.et al. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature. 323:1986;226-232.
3. Takahashi M., Cooper G.M. Ret transforming gene encodes a fusion protein homologous to tyrosine kinases. Mol. Cell Biol. 7:1987;1378-1385.
4. Qiu F.H., Ray P., Brown K., Barker P.E., Jhanwar S., Ruddle F.H.et al. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family - oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J. 7:1988;1003-1011.
5. Besmer P., Murphy J.E., George P.C., Qiu F.H., Bergold P.J., Lederman L.et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature. 320:1986;415-421.
6. Martin F.H., Suggs S.V., Langley K.E., Lu H.S., Ting J., Okino K.H.et al. Primary structure and functional expression of rat and human stem cell factor DNAs. Cell. 63:1990;203-211.
7. Zsebo K.M., Williams D.A., Geissler E.N., Broudy V.C., Martin F.H., Atkins H.L.et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell. 63:1990;213-224.
8. Zsebo K.M., Wypych J., McNiece I.K., Lu H.S., Smith K.A., Karkare S.B.et al. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver - conditioned medium. Cell. 63:1990;195-201.
9. Chabot B., Stephenson D.A., Chapman V.M., Besmer P., Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature. 335:1988;88-89.
10. Geissler E.N., Ryan M.A., Housman D.E. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell. 55:1988;185-192.
11. Geissler E.N., McFarland E.C., Russell E.S. Analysis of pleiotropism at the dominant white-spotting (W) locus of the house mouse: a description of ten new W alleles. Genetics. 97:1981;337-361.
12. Wiktor-Jedrzejczak W., Szczylik C., Gornas P., Sharkis S.J., Ahmed A. Haematopoiesis in mice heterozygous for the W trait: defective formation of transient endogenous spleen colonies. Cell Tissue Kinet. 14:1981;211-217.
13. d'Auriol L., Mattei M.G., Andre C., Galibert F. Localization of the human c-kit protooncogene on the q11-q12 region of chromosome 4. Hum. Genet. 78:1988;374-376.
14. Stenman G., Eriksson A., Claesson-Welsh L. Human PDGFA receptor gene maps to the same region on chromosome 4 as the KIT oncogene. Genes Chromosomes Cancer. 1:1989;155-158.
15. Fleischman R.A., Saltman D.L., Stastny V., Zneimer S. Deletion of the ckit protooncogene in the human developmental defect piebald trait. Proc. Natl. Acad. Sci. U.S.A. 88:1991;10885-10889.
16. Richmond A., Balentien E., Thomas H.G., Flaggs G., Barton D.E., Spiess J.et al. Molecular characterization and chromosomal mapping of melanoma growth stimulatory activity, a growth factor structurally related to beta-thromboglobulin. EMBO J. 7:1988;2025-2033.
17. Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S.et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:1998;577-580.
18. Nakahara M., Isozaki K., Hirota S., Miyagawa J., Hase-Sawada N., Taniguchi M.et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology. 115:1998;1090-1095.
19. Nishida T., Hirota S., Taniguchi M., Hashimoto K., Isozaki K., Nakamura H.et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat. Genet. 19:1998;323-324.
20. Hines S.J., Organ C., Kornstein M.J., Krystal G.W. Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ. 6:1995;769-779.
21. Rygaard K., Nakamura T., Spang-Thomsen M. Expression of the protooncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br. J. Cancer. 67:1993;37-46.
22. Stanulla M., Welte K., Hadam M.R., Pietsch T. Coexpression of stem cell factor and its receptor c-Kit in human malignant glioma cell lines. Acta Neuropathol. 89:1995;158-165.
23. Inoue M., Kyo S., Fujita M., Enomoto T., Kondoh G. Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res. 54:1994;3049-3053.
24. Reith A.D., Ellis C., Lyman S.D., Anderson D.M., Williams D.E., Bernstein A.et al. Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. EMBO J. 10:1991;2451-2459.
25. Zhu W.M., Dong W.F., Minden M. Alternate splicing creates two forms of the human kit protein. Leuk. Lymphoma. 12:1994;441-447.
26. Hayashi S., Kunisada T., Ogawa M., Yamaguchi K., Nishikawa S. Exon skipping by mutation of an authentic splice site of c-kit gene in W/W mouse. Nucleic Acids Res. 19:1991;1267-1271.
27. Caruana G., Cambareri A.C., Ashman L.K. Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts. Oncogene. 18:1999;5573-5581.
28. Blume-Jensen P., Siegbahn A., Stabel S., Heldin C.H., Ronnstrand L. Increased Kit/SCF receptor induced mitogenicity but abolished cell motility after inhibition of protein kinase C. EMBO J. 12:1993;4199-4209.
29. Blume-Jensen P., Wernstedt C., Heldin C.H., Ronnstrand L. Identification of the major phosphorylation sites for protein kinase C in kit/stem cell factor receptor in vitro and in intact cells. J. Biol. Chem. 270:1995;14192-14200.
30. Rottapel R., Reedijk M., Williams D.E., Lyman S.D., Anderson D.M., Pawson T.et al. The Steel/W transduction pathway: kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor. Mol. Cell Biol. 11:1991;3043-3051.
31. Tauchi T., Feng G.S., Marshall M.S., Shen R., Mantel C., Pawson T.et al. The ubiquitously expressed Syp phosphatase interacts with ckit and Grb2 in hematopoietic cells. J. Biol. Chem. 269:1994;25206-25211.
32. Yi T., Ihle J.N. Association of hematopoietic cell phosphatase with c-Kit after stimulation with c-Kit ligand. Mol. Cell Biol. 13:1993;3350-3358.
33. Tatosyan A.G., Mizenina O.A. Kinases of the Src family: structure and functions. Biochemistry (Mosc.). 65:2000;49-58.
34. Sicheri F., Kuriyan J. Structures of Src-family tyrosine kinases. Curr. Opin. Struct. Biol. 7:1997;777-785.
35. Voytyuk O., Lennartsson J., Mogi A., Caruana G., Courtneidge S., Ashman L.K.et al. Src family kinases are involved in the differential signaling from two splice forms of c-Kit. J. Biol. Chem. 278:2003;9159-9166.
36. Price D.J., Rivnay B., Fu Y., Jiang S., Avraham S., Avraham H. Direct association of Csk homologous kinase (CHK) with the diphosphorylated site Tyr568/570 of the activated c-KIT in megakaryocytes. J. Biol. Chem. 272:1997;5915-5920.
37. Linnekin D., DeBerry C.S., Mou S. Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells. J. Biol. Chem. 272:1997;27450-27455.
38. Lennartsson J., Blume-Jensen P., Hermanson M., Ponten E., Carlberg M., Ronnstrand L. Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene. 18:1999;5546-5553.
39. Krystal G.W., DeBerry C.S., Linnekin D., Litz J. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1. Cancer Res. 58:1998;4660-4666.
40. Cantley L.C. The phosphoinositide 3-kinase pathway. Science. 296:2002;1655-1657.
41. Okkenhaug K., Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 3:2003;317-330.
42. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer. 2:2002;489-501.
43. Serve H., Hsu Y.C., Besmer P. Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells. J. Biol. Chem. 269:1994;6026-6030.
44. Lev S., Givol D., Yarden Y. Interkinase domain of kit contains the binding site for phosphatidylinositol 3′ kinase. Proc. Natl. Acad. Sci. U.S.A. 89:1992;678-682.
45. Gaullier J.M., Simonsen A., D'Arrigo A., Bremnes B., Stenmark H., Aasland R. FYVE fingers bind PtdIns(3)P. Nature. 394:1998;432-433.
46. Lemmon M.A., Ferguson K.M., Schlessinger J. PH domains: diverse sequences with a common fold recruit signaling molecules to the cell surface. Cell. 85:1996;621-624.
47. Patki V., Lawe D.C., Corvera S., Virbasius J.V., Chawla A. A functional PtdIns(3)P-binding motif. Nature. 394:1998;433-434.
48. Rebecchi M.J., Scarlata S. Pleckstrin homology domains: a common fold with diverse functions. Annu. Rev. Biophys. Biomol. Struct. 27:1998;503-528.
49. Nishida K., Yoshida Y., Itoh M., Fukada T., Ohtani T., Shirogane T.et al. Gab-family adapter proteins act downstream of cytokine and growth factor receptors and Tand B-cell antigen receptors. Blood. 93:1999;1809-1816.
50. Nishida K., Wang L., Morii E., Park S.J., Narimatsu M., Itoh S.et al. Requirement of Gab2 for mast cell development and KitL/c-Kit signaling. Blood. 99:2002;1866-1869.
51. Ihle J.N. The Stat family in cytokine signaling. Curr. Opin. Cell Biol. 13:2001;211-217.
52. Ihle J.N., Nosaka T., Thierfelder W., Quelle F.W., Shimoda K. Jaks and Stats in cytokine signaling. Stem Cells. 15(Suppl 1):1997;105-111.
53. Brizzi M.F., Zini M.G., Aronica M.G., Blechman J.M., Yarden Y., Pegoraro L. Convergence of signaling by interleukin-3, granulocyte-macrophage colony-stimulating factor, and mast cell growth factor on JAK2 tyrosine kinase. J. Biol. Chem. 269:1994;31680-31684.
54. Weiler S.R., Mou S., DeBerry C.S., Keller J.R., Ruscetti F.W., Ferris D.K.et al. JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor. Blood. 87:1996;3688-3693.
55. Neubauer H., Cumano A., Muller M., Wu H., Huffstadt U., Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 93:1998;397-409.
56. Parganas E., Wang D., Stravopodis D., Topham D.J., Marine J.C., Teglund S.et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 93:1998;385-395.
57. Zhao S., Zoller K., Masuko M., Rojnuckarin P., Yang X.O., Parganas E.et al. JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cells. EMBO J. 21:2002;2159-2167.
58. Gotoh A., Takahira H., Mantel C., Litz-Jackson S., Boswell H.S., Broxmeyer H.E. Steel factor induces serine phosphorylation of Stat3 in human growth factor-dependent myeloid cell lines. Blood. 88:1996;138-145.
59. Deberry C., Mou S., Linnekin D. Stat1 associates with c-kit and is activated in response to stem cell factor. Biochem. J. 327(Pt 1):1997;73-80.
60. Ryan J.J., Huang H., McReynolds L.J., Shelburne C., Hu-Li J., Huff T.F. et al. Stem cell factor activates STAT-5 DNA binding in IL-3-derived bone marrow mast cells. Exp. Hematol. 25:1997;357-362.
61. Brizzi M.F., Dentelli P., Rosso A., Yarden Y., Pegoraro L. STAT protein recruitment and activation in c-Kit deletion mutants. J. Biol. Chem. 274:1999;16965-16972.
62. Lowenstein E.J., Daly R.J., Batzer A.G., Li W., Margolis B., Lammers R. et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell. 70:1992;431-442.
63. Thommes K., Lennartsson J., Carlberg M., Ronnstrand L. Identification of Tyr-703 and Tyr-936 as the primary association sites for Grb2 and Grb7 in the c-Kit/stem cell factor receptor. Biochem. J. 341(Pt 1):1999;211-216.
64. Hibi M., Hirano T. Gab-family adapter molecules in signal transduction of cytokine and growth factor receptors, and T and B cell antigen receptors. Leuk. Lymphoma. 37:2000;299-307.
65. Lee J.T. Jr., McCubrey J.A. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia. 16:2002;486-507.
66. Herbst R., Shearman M.S., Jallal B., Schlessinger J., Ullrich A. Formation of signal transfer complexes between stem cell and platelet-derived growth factor receptors and SH2 domain proteins in vitro. Biochemistry. 34:1995;5971-5979.
67. Fukami K. Structure, regulation, and function of phospholipase C isozymes. J. Biochem. (Tokyo). 131:2002;293-299.
68. Plo I., Lautier D., Casteran N., Dubreuil P., Arock M., Laurent G. Kit signaling and negative regulation of daunorubicin-induced apoptosis: role of phospholipase Cgamma. Oncogene. 20:2001;6752-6763.
69. Guan K.L., Dixon J.E. Evidence for protein-tyrosine-phosphatase catalysis proceeding via a cysteine-phosphate intermediate. J. Biol. Chem. 266:1991;17026-17030.
70. Barrett W.C., DeGnore J.P., Keng Y.F., Zhang Z.Y., Yim M.B., Chock P.B. Roles of superoxide radical anion in signal transduction mediated by reversible regulation of protein-tyrosine phosphatase 1B. J. Biol. Chem. 274:1999;34543-34546.
71. Denu J.M., Tanner K.G. Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation. Biochemistry. 37:1998;5633-5642.
72. Sattler M., Winkler T., Verma S., Byrne C.H., Shrikhande G., Salgia R.et al. Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood. 93:1999;2928-2935.
73. Wang W.L., Healy M.E., Sattler M., Verma S., Lin J., Maulik G.et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 19:2000;3521-3528.
74. Kozlowski M., Larose L., Lee F., Le D.M., Rottapel R., Siminovitch K.A. SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain. Mol. Cell Biol. 18:1998;2089-2099.
75. Lorenz U., Bergemann A.D., Steinberg H.N., Flanagan J.G., Li X., Galli S.J.et al. Genetic analysis reveals cell type-specific regulation of receptor tyrosine kinase c-Kit by the protein tyrosine phosphatase SHP1. J. Exp. Med. 184:1996;1111-1126.
76. Paulson R.F., Vesely S., Siminovitch K.A., Bernstein A. Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1. Nat. Genet. 13:1996;309-315.
77. Rohrschneider L.R., Fuller J.F., Wolf I., Liu Y., Lucas D.M. Structure, function, and biology of SHIP proteins. Genes Dev. 14:2000;505-520.
78. Leslie N.R., Downes C.P. PTEN: The down side of PI 3-kinase signalling. Cell Signal. 14:2002;285-295.
79. Yamada K.M., Araki M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J. Cell Sci. 114:2001;2375-2382.
80. Huber M., Helgason C.D., Scheid M.P., Duronio V., Humphries R.K., Krystal G. Targeted disruption of SHIP leads to Steel factor-induced degranulation of mast cells. EMBO J. 17:1998;7311-7319.
81. Liu Q., Sasaki T., Kozieradzki I., Wakeham A., Itie A., Dumont D.J.et al. SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev. 13:1999;786-791.
82. Aman M.J., Lamkin T.D., Okada H., Kurosaki T., Ravichandran K.S. The inositol phosphatase SHIP inhibits Akt/PKB activation in B cells. J. Biol. Chem. 273:1998;33922-33928.
83. Musashi M., Ota S., Shiroshita N. The role of protein kinase C isoforms in cell proliferation and apoptosis. Int. J. Hematol. 72:2000;12-19.
84. Gomez D.E., Skilton G., Alonso D.F., Kazanietz M.G. The role of protein kinase C and novel phorbol ester receptors in tumor cell invasion and metastasis (Review). Oncol. Rep. 6:1999;1363-1370.
85. Dempsey E.C., Newton A.C., Mochly-Rosen D., Fields A.P., Reyland M.E., Insel P.A.et al. Protein kinase C isozymes and the regulation of diverse cell responses. Am. J. Physiol. Lung Cell Mol. Physiol. 279:2000;L429-L438.
86. Blume-Jensen P., Ronnstrand L., Gout I., Waterfield M.D., Heldin C.H. Modulation of Kit/stem cell factor receptor-induced signaling by protein kinase C. J. Biol. Chem. 269:1994;21793-21802.
87. Brizzi M.F., Blechman J.M., Cavalloni G., Givol D., Yarden Y., Pegoraro L. Protein kinase C-dependent release of a functional whole extracellular domain of the mast cell growth factor (MGF) receptor by MGF dependent human myeloid cells. Oncogene. 9:1994;1583-1589.
88. Vosseller K., Stella G., Yee N.S., Besmer P. c-kit receptor signaling through its phosphatidylinositide-3′-kinase-binding site and protein kinase C: role in mast cell enhancement of degranulation, adhesion, and membrane ruffling. Mol. Biol. Cell. 8:1997;909-922.
89. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J.et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295:2000;139-145.
90. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 96:2000;925-932.
91. Krystal G.W., Honsawek S., Litz J., Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin. Cancer Res. 6:2000;3319-3326.
92. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Druker B.J. et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56:1996;100-104.
93. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S.et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:1996;561-566.
94. Buchdunger E., O'Reilly T., Wood J. Pharmacology of imatinib (STI571). Eur. J. Cancer. 38(Suppl 5):2002;S28-S36.
95. Tuveson D.A., Willis N.A., Jacks T., Griffin J.D., Singer S., Fletcher C.D.et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 20:2001;5054-5058.
96. Joensuu H., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D.et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344:2001;1052-1056.
97. Wisniewski D., Lambek C.L., Liu C., Strife A., Veach D.R., Nagar B.et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res. 62:2002;4244-4255.
98. Krystal G.W., Honsawek S., Kiewlich D., Liang C., Vasile S., Sun L.et al. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res. 61:2001;3660-3668.
99. Smolich B.D., Yuen H.A., West K.A., Giles F.J., Albitar M., Cherrington J.M. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood. 97:2001;1413-1421.
100. Kovalenko M., Gazit A., Bohmer A., Rorsman C., Ronnstrand L., Heldin C.H.et al. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 54:1994;6106-6114.
101. Tse K.F., Novelli E., Civin C.I., Bohmer F.D., Small D. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia. 15:2001;1001-1010.
102. Fletcher C.D., Berman J.J., Corless C., Gorstein F., Lasota J., Longley B.J.et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum. Pathol. 33:2002;459-465.
103. Isozaki K., Hirota S., Nakama A., Miyagawa J., Shinomura Y., Xu Z.et al. Disturbed intestinal movement, bile reflux to the stomach, and deficiency of c-kit-expressing cells in Ws/Ws mutant rats. Gastroenterology. 109:1995;456-464.
104. Rubin B.P., Singer S., Tsao C., Duensing A., Lux M.L., Ruiz R.et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61:2001;8118-8121.
105. Lux M.L., Rubin B.P., Biase T.L., Chen C.J., Maclure T., Demetri G.et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am. J. Pathol. 156:2000;791-795.
106. Moskaluk C.A., Tian Q., Marshall C.R., Rumpel C.A., Franquemont D.W., Frierson H.F. Jr. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene. 18:1999;1897-1902.
107. Taniguchi M., Nishida T., Hirota S., Isozaki K., Ito T., Nomura T.et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 59:1999;4297-4300.
108. Schneider-Stock R., Boltze C., Lasota J., Miettinen M., Peters B., Pross M.et al. High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. J. Clin. Oncol. 21:2003;1688-1697.
109. Heinrich M.C., Corless C.L., Duensing A., McGreevey L., Chen C.J., Joseph N.et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 299:2003;708-710.
110. Kim N.G., Kim J.J., Ahn J.Y., Seong C.M., Noh S.H., Kim C.B.et al. Putative chromosomal deletions on 9P, 9Q and 22Q occur preferentially in malignant gastrointestinal stromal tumors. Int. J. Cancer. 85:2000;633-638.
111. Debiec-Rychter M., Lasota J., Sarlomo-Rikala M., Kordek R., Miettinen M. Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. Cancer Genet. Cytogenet. 128:2001;24-30.
112. O'Leary T., Ernst S., Przygodzki R., Emory T., Sobin L. Loss of heterozygosity at 1p36 predicts poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab. Invest. 79:1999;1461-1467.
113. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J.et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347:2002;472-480.
114. Middelkamp Hup M.A., Heide R., Tank B., Mulder P.G., Oranje A.P. Comparison of mastocytosis with onset in children and adults. J. Eur. Acad. Dermatol. Venereol. 16:2002;115-120.
115. Tharp M.D., Longley B.J. Jr. Mastocytosis. Dermatol. Clin. 19:2001;679-696. viii-ix.
116. Simpson J.K., Metcalfe D.D. Mastocytosis and disorders of mast cell proliferation. Clin. Rev. Allergy Immunol. 22:2002;175-188.
117. Longley B.J. Jr., Metcalfe D.D., Tharp M., Wang X., Tyrrell L., Lu S.Z. et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc. Natl. Acad. Sci. U.S.A. 96:1999;1609-1614.
118. Nagata H., Worobec A.S., Oh C.K., Chowdhury B.A., Tannenbaum S., Suzuki Y.et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. U.S.A. 92:1995;10560-10564.
119. Kanakura Y., Furitsu T., Tsujimura T., Butterfield J.H., Ashman L.K., Ikeda H.et al. Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. Leukemia. 8(Suppl 1):1994;S18-22.
120. Furitsu T., Tsujimura T., Tono T., Ikeda H., Kitayama H., Koshimizu U.et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92:1993;1736-1744.
121. Ma Y., Zeng S., Metcalfe D.D., Akin C., Dimitrijevic S., Butterfield J.H.et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wildtype kinases and those with regulatory-type mutations. Blood. 99:2002;1741-1744.
122. Sattler M., Salgia R. Molecular and cellular biology of small cell lung cancer. Semin. Oncol. 30:2003;57-71.
123. Sekido Y., Obata Y., Ueda R., Hida T., Suyama M., Shimokata K.et al. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res. 51:1991;2416-2419.
124. Krystal G.W., Hines S.J., Organ C.P. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res. 56:1996;370-376.
125. Maulik G., Kijima T., Ma P.C., Ghosh S.K., Lin J., Shapiro G.I.et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin. Cancer Res. 8:2002;620-627.
126. Johnson B.E., Fisher B., Fisher T., Dunlop D., Rischin D., Silberman S. et al. Phase II study of STI571 (Gleevec) for patients with small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 21:2002;293a.
127. Murty V.V., Chaganti R.S. A genetic perspective of male germ cell tumors. Semin. Oncol. 25:1998;133-144.
128. Kollmannsberger C., Mayer F., Kuczyk M., Kanz L., Bokemeyer C. Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy. World J. Urol. 19:2001;120-125.
129. Toner G.C., Frydenberg M. Poor prognosis germ-cell tumors: an unresolved challenge. Semin. Urol. Oncol. 20:2002;251-261.
130. Bokemeyer C., Kuczyk M.A., Dunn T., Serth J., Hartmann K., Jonasson J., et al. Expression of stem-cell factor and its receptor c-kit protein in normal testicular tissue and malignant germ-cell tumours. J. Cancer Res. Clin. Oncol. 122:1996;301-306.
131. Rajpert-De Meyts E., Skakkebaek N.E. Expression of the c-kit protein product in carcinoma-in-situ and invasive testicular germ cell tumours. Int. J. Androl. 17:1994;85-92.
132. Strohmeyer T., Reese D., Press M., Ackermann R., Hartmann M., Slamon D. Expression of the c-kit proto-oncogene and its ligand stem cell factor (SCF) in normal and malignant human testicular tissue. J. Urol. 153:1995;511-515.
133. Kollmannsberger C., Mayer F., Pressler H., Koch S., Kanz L., Oosterhuis J.W., et al. Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. Cancer. 95:2002;301-308.
134. Tian Q., Frierson H.F. Jr., Krystal G.W., Moskaluk C.A. Activating c-kit gene mutations in human germ cell tumors. Am. J. Pathol. 154:1999;1643-1647.
135. Przygodzki R.M., Hubbs A.E., Zhao F.Q., O'Leary T.J. Primary mediastinal seminomas: evidence of single and multiple KIT mutations. Lab. Invest. 82:2002;1369-1375.
136. Sakuma Y., Sakurai S., Oguni S., Hironaka M., Saito K. Alterations of the c-kit gene in testicular germ cell tumors. Cancer Sci. 94:2003;486-491.
137. Natali P.G., Berlingieri M.T., Nicotra M.R., Fusco A., Santoro E., Bigotti A., et al. Transformation of thyroid epithelium is associated with loss of c-kit receptor. Cancer Res. 55:1995;1787-1791.
138. Toyota M., Hinoda Y., Takaoka A., Makiguchi Y., Takahashi T., Itoh F., et al. Expression of c-kit and kit ligand in human colon carcinoma cells. Tumour Biol. 14:1993;295-302.
139. Beck D., Gross N., Brognara C.B., Perruisseau G. Expression of stem cell factor and its receptor by human neuroblastoma cells and tumors. Blood. 86:1995;3132-3138.